AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30981962 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 42
Study 28334999 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electro-acupuncture 'local' to the more affected hand
Number of subjects: 80
Study 28334999 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electro-acupuncture at 'distal' body sites, near the ankle contralesional to the more affected hand
Number of subjects: 80
Study 28334999 — intervention group
Group type: COMPARATOR
Intervention: Local sham electro-acupuncture using non-penetrating placebo needles
Number of subjects: 80
Study 26404947 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with regular fluoride toothpaste followed by rinsing with a 0.075% cetylpyridinium chloride (CPC) mouthwash
Number of subjects: 70
Study 26404947 — intervention group
Group type: COMPARATOR
Intervention: Brushing with regular fluoride toothpaste alone (control group)
Number of subjects: 70
Study 23649906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic saline (pH 3.3) injection
Number of subjects: 18
Study 23649906 — intervention group
Group type: COMPARATOR
Intervention: Regular isotonic saline injection
Number of subjects: 18
Study 23649906 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injection of acidic saline
Number of subjects: 18
Study 23649906 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections (both acidic and regular saline)
Number of subjects: 18
Study 20220040 — intervention group
Group type: COMPARATOR
Intervention: L-DOPS + Placebo (PLA)
Number of subjects: 12
Study 20220040 — intervention group
Group type: COMPARATOR
Intervention: L-DOPS + Entacapone (ENT)
Number of subjects: 12
Study 20220040 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPS + Carbidopa (CAR)
Number of subjects: 12
Study 19451574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide, 15 mg/kg every 2 to 3 weeks
Number of subjects: 149
Study 19451574 — intervention group
Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide, 2 mg/kg per day
Number of subjects: 149
Study 16797591 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 172
Study 15801333 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 36
Study 15801333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11355559 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice a day, in 3 cycles of 6 weeks with 2 weeks between cycles)
Number of subjects: 29
Study 11355559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11355559 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 29
Study 9417436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionomeric cement used for reconstruction of the ossicular chain
Number of subjects: 0
Study 9417436 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-gold-angle prostheses crimped to the long process of the incus
Number of subjects: 0
Study 7952663 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical tibial prosthetic base plate
Number of subjects: 0
Study 7952663 — intervention group
Group type: COMPARATOR
Intervention: Commercial prosthesis
Number of subjects: 0
Study 3570029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 6
Study 3570029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 6
Study 3570029 — intervention group
Group type: COMPARATOR
Intervention: Neomycin with lactulose
Number of subjects: 6
Study 2506091 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (twice daily for 6 months)
Number of subjects: 24
Study 2506091 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide and metformin combination therapy (for 6 months)
Number of subjects: 24
Study 4599014 — intervention group
Group type: EXPERIMENTAL
Intervention: Midrin (M)
Number of subjects: 60
Study 4599014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometheptene mucate (I)
Number of subjects: 60
Study 4599014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study 30771133 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (35 HIV risk reduction and HIV testing SMSs over a 6-month period)
Number of subjects: 0
Study 30771133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28561278 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 100
Study 28561278 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 25714579 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E, Metformin, or Placebo (Control) for 96 weeks
Number of subjects: 173
Study 23429997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: pedicle screws
Number of subjects: 36
Study 23429997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: long-head pedicle screws
Number of subjects: 36
Study 23429997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: additional Ponte osteotomy
Number of subjects: 36
Study 23429997 — intervention group
Group type: COMPARATOR
Intervention: Group B and C
Number of subjects: 36
Study 23429997 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 21829197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 107
Study 21829197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 19900934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (detailed training programme before discharge and at five follow‐up visits during 24 months)
Number of subjects: 314
Study 19900934 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow‐up visits without instructions in physical activity)
Number of subjects: 314
Study 19900934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 314
Study 19900934 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study 17118858 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise, walking exercise, group exercise, and self-care exercise
Number of subjects: 555
Study 17118858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 555
Study 15006954 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg qd for 5 days)
Number of subjects: 730
Study 15006954 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (amoxicillin [500 mg tid for 7 days], clarithromycin [500 mg bid for 7 days], or cefuroxime‐axetil [250 mg bid for 7 days])
Number of subjects: 730
Study 11396202 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 606
Study 11396202 — intervention group
Group type: COMPARATOR
Intervention: CYP1A1 genotype
Number of subjects: 606
Study 9422470 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 10 microg/kg/day + GM‐CSF 5 microg/kg/day (arm II)
Number of subjects: 50
Study 9422470 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF 10 microg/kg/day alone (arm I)
Number of subjects: 50
Study 8486084 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.2‐0.6 mg/kg)
Number of subjects: 10
Study 8486084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3322376 — intervention group
Group type: EXPERIMENTAL
Intervention: Epostane (progesterone synthesis inhibitor)
Number of subjects: 0
Study 3322376 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 31345146 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12
Number of subjects: 240
Study 31345146 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid alone
Number of subjects: 240
Study 31345146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 alone
Number of subjects: 240
Study 31345146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 240
Study 28321455 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention for khat users
Number of subjects: 330
Study 25907821 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized medical treatment of COPD
Number of subjects: 130
Study 25907821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 25907821 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up in pulmonary clinic for 24 weeks
Number of subjects: 130
Study 23294275 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (10 mg) in subjects with mild hepatic impairment
Number of subjects: 32
Study 23294275 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (10 mg) in subjects with moderate hepatic impairment
Number of subjects: 32
Study 23294275 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 32
Study 21199175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenously)
Number of subjects: 11
Study 21199175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18068522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg enteric-coated tablet per day)
Number of subjects: 310
Study 18068522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 310
Study 18068522 — intervention group
Group type: COMPARATOR
Intervention: Control (aspirin avoidance)
Number of subjects: 310
Study 16595222 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice daily) and clomiphene citrate (100 mg from the third day for 5 days)
Number of subjects: 25
Study 16595222 — intervention group
Group type: COMPARATOR
Intervention: metformin (500 mg three times daily) and clomiphene citrate (100 mg from the third day for 5 days)
Number of subjects: 25
Study 12914827 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling on physical activity and individual counseling on healthy food habits (intervention group)
Number of subjects: 169
Study 12914827 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 169
Study 12914827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 169
Study 10489668 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuhaler
Number of subjects: 0
Study 10489668 — intervention group
Group type: EXPERIMENTAL
Intervention: Autohaler
Number of subjects: 0
Study 10489668 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 0
Study 8613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 0
Study 8613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) infusion
Number of subjects: 0
Study 8613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ANP and BNP infusions
Number of subjects: 0
Study 8613267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1748538 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg intravenous metronidazole
Number of subjects: 9
Study 1748538 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 gm intravenous metronidazole
Number of subjects: 9
Study 1748538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 gm intravenous metronidazole
Number of subjects: 9
Study 1748538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of metronidazole (1.0 gm and 2.0 gm)
Number of subjects: 9
Study 6412738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 0
Study 6412738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 0
Study 6412738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of steroids and SCG
Number of subjects: 0
Study 6412738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27464622 — intervention group
Group type: EXPERIMENTAL
Intervention: WI9 (8.6 ± 0.2°C)
Number of subjects: 9
Study 27464622 — intervention group
Group type: EXPERIMENTAL
Intervention: WI15 (14.6 ± 0.3°C)
Number of subjects: 9
Study 27464622 — intervention group
Group type: EXPERIMENTAL
Intervention: WI35 (35.0 ± 0.4°C)
Number of subjects: 9
Study 27464622 — intervention group
Group type: COMPARATOR
Intervention: Passive rest (CON)
Number of subjects: 9
Study 27152579 — intervention group
Group type: EXPERIMENTAL
Intervention: Double small incisions (Group A)
Number of subjects: 207
Study 27152579 — intervention group
Group type: COMPARATOR
Intervention: Standard incision (Group B)
Number of subjects: 207
Study 27152579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release (Group C)
Number of subjects: 207
Study 24823696 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 0
Study 24823696 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 24823696 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib and Sorafenib
Number of subjects: 0
Study 21041836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment alone
Number of subjects: 110
Study 21041836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment combined with thermocycling (FS + Th)
Number of subjects: 110
Study 21041836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 110
Study 20430500 — intervention group
Group type: COMPARATOR
Intervention: Folate (15 mg/d)
Number of subjects: 40
Study 20430500 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of folate (15 mg/d) and methylcobalamin (500 mug after each hemodialysis treatment 3 times weekly)
Number of subjects: 40
Study 19186852 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF group (1450 mg/L sodium fluoride dentifrice)
Number of subjects: 305
Study 19186852 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP group (1450 mg/L sodium monofluorophosphate dentifrice)
Number of subjects: 305
Study 19186852 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride group (non-fluoride dentifrice)
Number of subjects: 305
Study 15806596 — intervention group
Group type: EXPERIMENTAL
Intervention: PCD children
Number of subjects: 20
Study 12024846 — intervention group
Group type: EXPERIMENTAL
Intervention: Active reflexology
Number of subjects: 40
Study 12024846 — intervention group
Group type: COMPARATOR
Intervention: Simulated (placebo) reflexology
Number of subjects: 40
Study 9485231 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (15-g bolus + infusion of 1 g/h)
Number of subjects: 134
Study 9485231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10-g bolus + placebo infusion)
Number of subjects: 134
Study 9485231 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 134
Study 7610155 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min exercise bout at an intensity of 60% VO2max
Number of subjects: 11
Study 7610155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RQ (high fat oxidation)
Number of subjects: 11
Study 7610155 — intervention group
Group type: EXPERIMENTAL
Intervention: High RQ
Number of subjects: 11
Study 7610155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise RQ
Number of subjects: 11
Study 2147014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic preparation containing ethinylestradiol and desogestrel (M‐DG)
Number of subjects: 58
Study 2147014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic preparation containing ethinylestradiol and gestodene (M‐GD)
Number of subjects: 58
Study 2147014 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic preparation of ethinylestradiol and levonorgestrel (T‐LN)
Number of subjects: 58
Study 2147014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 12
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 12
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine + Isoprenaline
Number of subjects: 12
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (in non-responders)
Number of subjects: 12
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (in allergic bronchial asthma)
Number of subjects: 12
Study 918356 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (in allergic bronchial asthma)
Number of subjects: 12
Study 30984388 — intervention group
Group type: EXPERIMENTAL
Intervention: Receive a pen with the invitation pack (n = 648)
Number of subjects: 1862
Study 30984388 — intervention group
Group type: COMPARATOR
Intervention: No pen with the invitation pack (n = 1295)
Number of subjects: 1862
Study 28436154 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n = 219)
Number of subjects: 439
Study 28436154 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 220)
Number of subjects: 439
Study 25108589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonic speakers
Number of subjects: 40
Study 25108589 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 23417625 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training Group-based Program (SST-GP)
Number of subjects: 0
Study 23417625 — intervention group
Group type: COMPARATOR
Intervention: Leisure Activities Group-based Program (LA-GP)
Number of subjects: 0
Study 21321791 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-besilesomab (Scintimun)
Number of subjects: 119
Study 21321791 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-HMPAO-labelled white blood cells (WBCs)
Number of subjects: 119
Study 19376310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078
Study 19376310 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study 17845881 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-walking exercise prescription
Number of subjects: 103
Study 14718430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicomandibular support collar (CMSC)
Number of subjects: 10
Study 14718430 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 10
Study 11294692 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (90 min of brisk walking the day before)
Number of subjects: 11
Study 11294692 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 11
Study 9391992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micrograms) biweekly
Number of subjects: 30
Study 9391992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 micrograms) biweekly
Number of subjects: 30
Study 9391992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 30
Study 9391992 — intervention group
Group type: COMPARATOR
Intervention: GH-RH stimulation test
Number of subjects: 30
Study 8934730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU
Number of subjects: 0
Study 8934730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU with leucovorin or interferon
Number of subjects: 0
Study 8934730 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-modulated infusional 5-FU
Number of subjects: 0
Study 8934730 — intervention group
Group type: COMPARATOR
Intervention: Bolus single agent 5-FU
Number of subjects: 0
Study 2212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 2212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 340942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times a day)
Number of subjects: 1475
Study 340942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1475
Study 30806758 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI/CDDP (IRI, 60 mg/m2; CDDP, 30 mg/m2, q2w)
Number of subjects: 108
Study 30806758 — intervention group
Group type: COMPARATOR
Intervention: IRI (150 mg/m2, q2w)
Number of subjects: 108
Study 30806758 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI/CDDP
Number of subjects: 108
Study 30806758 — intervention group
Group type: COMPARATOR
Intervention: IRI
Number of subjects: 108
Study 28882634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) applied over M1 on Day 1 during reinforcement learning
Number of subjects: 50
Study 28882634 — intervention group
Group type: COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS) applied over M1 on Day 3 after consolidation
Number of subjects: 50
Study 28882634 — intervention group
Group type: COMPARATOR
Intervention: cTBS applied on Day 2 in a recent study (Derosiere et al., 2017)
Number of subjects: 50
Study 24616488 — intervention group
Group type: EXPERIMENTAL
Intervention: Test light (515 nm) after exposure to longer wavelength light (589 nm)
Number of subjects: 16
Study 24616488 — intervention group
Group type: COMPARATOR
Intervention: Test light (515 nm) after exposure to shorter wavelength light (461 nm)
Number of subjects: 16
Study 22176808 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (1 g/kg)
Number of subjects: 8
Study 22176808 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.4% hypertonic saline (0.686 mL/kg)
Number of subjects: 8
Study 19997098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of a single dose of testosterone
Number of subjects: 0
Study 19997098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (belief of receiving testosterone)
Number of subjects: 0
Study 18996862 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental modified starch therapy (100 g digestible starch)
Number of subjects: 12
Study 18996862 — intervention group
Group type: COMPARATOR
Intervention: Traditional uncooked cornstarch therapy (100 g)
Number of subjects: 12
Study 15811983 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received suicide questions)
Number of subjects: 2342
Study 15811983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk students in experimental group (received suicide questions)
Number of subjects: 2342